Traficet-EN: Completed Phase II/III enrollment

ChemoCentryx completed enrollment of 436 patients with moderate to severe Crohn’s disease in the double-blind, placebo-controlled, international Phase II/III PROTECT-1 trial of oral Traficet-EN. ...